Inventiva SA has announced leadership changes with the appointment of Jason Campagna, MD, PhD, as President of Research and Development and Chief Medical Officer, and Martine Zimmermann, PharmD, as Executive Vice President of Regulatory Affairs and Quality Assurance. These appointments come as the company prepares for the NATiV3 Phase 3 study results expected in the second half of 2026. Dr. Campagna brings experience from Q32 Bio and Intercept Pharmaceuticals, while Dr. Zimmermann joins from Ipsen, where she led regulatory efforts for liver disease drugs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inventiva SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001117255-en) on July 09, 2025, and is solely responsible for the information contained therein.